A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

NCT ID: NCT03693391

Last Updated: 2025-04-27

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-17
• Study Completion Date: 2019-03-13

Brief Summary

The purpose of this study is to measure the blocking of [18F]JNJ-64511070 binding in the brain at the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination (tmax) of JNJ-64140284 and determine the exposure/receptor interaction of JNJ-64140284 in healthy male participants following single oral dose administration of JNJ-64140284.

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Cohort 1: JNJ-64140284

Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of \[18F\]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.

Group Type: EXPERIMENTAL

JNJ-64140284

Intervention Type: DRUG

Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Fluorine-18 Labeled [18F]-JNJ-64511070

Intervention Type: DRUG

An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Cohort 2: JNJ-64140284

Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.

Group Type: EXPERIMENTAL

JNJ-64140284

Intervention Type: DRUG

Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Fluorine-18 Labeled [18F]-JNJ-64511070

Intervention Type: DRUG

An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Cohort 3: JNJ-64140284

Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.

Group Type: EXPERIMENTAL

JNJ-64140284

Intervention Type: DRUG

Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Fluorine-18 Labeled [18F]-JNJ-64511070

Intervention Type: DRUG

An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Cohort 4: JNJ-64140284

Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.

Group Type: EXPERIMENTAL

JNJ-64140284

Intervention Type: DRUG

Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Fluorine-18 Labeled [18F]-JNJ-64511070

Intervention Type: DRUG

An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Interventions

JNJ-64140284

Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Intervention Type: DRUG

Fluorine-18 Labeled [18F]-JNJ-64511070

An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m^2) inclusive (Body Mass Index [BMI] = weight/height^2)
• Non-smoker (not smoked for 3 months prior to screening) or/and has not used nicotine -containing products (for example, nicotine patch) for 3 months prior to screening
• Is willing to allow the investigators to place an arterial catheter in the radial artery, is assessed via physical examination (Allen Test) to be a good candidate for arterial catheter placement
• Has no history or laboratory evidence of a coagulopathy. (for participants undergoing positron emission tomography [PET] scan only)
• During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the highly effective method of contraception, a man a) who is sexually active with a woman of childbearing potential and has not had vasectomy must agree to use a condom and their female partner should also use oral contraception or user independent method such as intrauterine device (IUD) or hormonal implant for at least the same duration; b) who is sexually active with a woman who is pregnant, must use a condom; c) must agree not to donate sperm

Exclusion Criteria

• Exposed to greater than (>)1 milliSievert (mSv) of ionizing radiation participating as a participant in research studies 12 months before the start of this study
• Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the investigator are acceptable
• Clinically significant abnormal physical and neurological examination, vital signs or 12-lead electrocardiogram (ECG) at screening or admission
• History of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, liver or renal disease or obstruction to urinary flow, infection, or any other condition that the Investigator considers significant should exclude the participant. History of epilepsy or fits or unexplained black-outs
• Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or human immunodeficiency virus (HIV) antibodies unless the participant has been successfully treated for HCV or HIV. Successful treatment should be confirmed by a negative ribonucleic acid (RNA) test for the virus

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

UZ Leuven Gasthuisberg

Leuven, , Belgium

Countries

Belgium

Other Identifiers

64140284EDI1003

Identifier Type: OTHER

Identifier Source: secondary_id

2018-002539-98

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR108508

Identifier Type: -

Identifier Source: org_study_id